Eureka Equity Partners (“Eureka”) today announced the sale of MedForce, a leading medical communications company specializing in scientific content development and healthcare professional interaction management services that drive successful product commercialization for its biopharma clients, to an undisclosed strategic buyer.
Based in Shrewsbury, NJ, MedForce leverages deep scientific expertise in highly complex oncology, rare disease and specialty drugs to meet the growing demand for product-specific messaging and flawless compliance with complex state and federal regulations. With aiovance, its proprietary technology platform, and integrated solutions across its whole portfolio of services, MedForce delivers biopharma clients a comprehensive medical communications strategy throughout the entire product lifecycle and is uniquely suited to manage the seamless transition from medical affairs through commercialization to maturity.
“We’ve been honored to work with CEO Tim Fallon, President Mike Basta and the rest of MedForce’s outstanding management team to help build an industry leader with unmatched expertise in the complex scientific market it serves and robust tech-enabled service offerings that yield unparalleled customer service,” said Chris Miller, a Partner at Eureka and former Director of MedForce. “The MedForce team excels in designing and executing data-informed brand strategies that educate healthcare professionals and enhance awareness and understanding of client brands,” added Tassie Oswald, a Partner at Eureka and former Director of MedForce. “These capabilities make MedForce a trusted partner to its customers throughout the entire lifecycle of a product and will continue to drive growth and success for the company.”
“Eureka has been instrumental in the growth of MedForce into a market leader in the medical communications space,” said MedForce’s President Mike Basta. “Our partnership with Eureka provided us with financial and strategic support to innovate technologically, acquire scientific content development expertise, scale our business, and integrate our capabilities into a single solution for our biopharmaceutical clients. Eureka was the ideal partner to support the growth and expansion of MedForce.”
“Eureka proved to be an exceptional partner from the inception of our relationship through the entire transaction process, and we are absolutely delighted with the outcome,” said CEO Tim Fallon, adding, “Their unwavering involvement and support at every stage played a pivotal role in achieving such a successful result. We couldn’t be more pleased with Eureka’s invaluable contribution to making this transaction happen.”
Piper Sandler & Co. served as financial advisor and Morgan, Lewis & Bockius LLP acted as legal advisor to Eureka and MedForce.